We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04183790




Registration number
NCT04183790
Ethics application status
Date submitted
28/11/2019
Date registered
3/12/2019
Date last updated
10/02/2021

Titles & IDs
Public title
Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
Scientific title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
Secondary ID [1] 0 0
2019-001827-11
Secondary ID [2] 0 0
VX19-445-107
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Cystic fibrosis
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - ELX/TEZ/IVA
Treatment: Drugs - IVA

Experimental: Triple Combination Arm - Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.


Treatment: Drugs: ELX/TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration

Treatment: Drugs: IVA
Mono tablet for oral administration.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability as assessed by adverse events (AEs) and serious adverse events (SAEs)
Timepoint [1] 0 0
From Baseline up to Week 100
Secondary outcome [1] 0 0
Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)
Timepoint [1] 0 0
From Baseline up to Week 96
Secondary outcome [2] 0 0
Absolute change in sweat chloride (SwCl)
Timepoint [2] 0 0
From Baseline up to Week 96
Secondary outcome [3] 0 0
Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score
Timepoint [3] 0 0
From Baseline up to Week 96
Secondary outcome [4] 0 0
Absolute change in body mass index (BMI)
Timepoint [4] 0 0
From Baseline up to Week 96
Secondary outcome [5] 0 0
Absolute change in BMI-for-age z-score
Timepoint [5] 0 0
From Baseline up to Week 96
Secondary outcome [6] 0 0
Number of pulmonary exacerbations (PEx)
Timepoint [6] 0 0
From Baseline up to Week 96
Secondary outcome [7] 0 0
Number of CF-related hospitalizations
Timepoint [7] 0 0
From Baseline up to Week 96
Secondary outcome [8] 0 0
Absolute change in lung clearance index 2.5 (LCI 2.5)
Timepoint [8] 0 0
From Baseline up to Week 96
Secondary outcome [9] 0 0
Absolute change in weight
Timepoint [9] 0 0
From Baseline up to Week 96
Secondary outcome [10] 0 0
Absolute change in weight-for-age z-score
Timepoint [10] 0 0
From Baseline up to Week 96
Secondary outcome [11] 0 0
Absolute change in height
Timepoint [11] 0 0
From Baseline up to Week 96
Secondary outcome [12] 0 0
Absolute change in height-for-age z-score
Timepoint [12] 0 0
From Baseline up to Week 96

Eligibility
Key inclusion criteria
Key

- Completed study drug treatment in parent study (VX18-445-106 Part B, NCT03691779), or
had study drug interruption(s) in parent study but completed study visits up to the
last scheduled visit of the Treatment Period in the parent study

Key
Minimum age
6 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of study drug intolerance in parent study

Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [2] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
- South Brisbane
Recruitment postcode(s) [2] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Minnesota
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
Canada
State/province [13] 0 0
Toronto
Country [14] 0 0
Canada
State/province [14] 0 0
Vancouver
Country [15] 0 0
Ireland
State/province [15] 0 0
Dublin
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Birmingham
Country [17] 0 0
United Kingdom
State/province [17] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vertex Pharmaceuticals Incorporated
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics
of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor
(IVA) in subjects with cystic fibrosis (CF).
Trial website
https://clinicaltrials.gov/show/NCT04183790
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications